Latest News
Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Estimates – NASDAQ:CGTX
- Cognition Therapeutics aligns with FDA on Phase 3 trial of zervimesine
- Form 8K Cognition Therapeutics Inc For: 22 October By Investing.com
- Cognition aligns with FDA on phase 3 trial design for DLB
- Cognition Therapeutics aligns with FDA on Phase 3 trial design for dementia drug Zervimesine.
- Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
- Cognition Therapeutics Aligns with FDA on Planned Phase 3 DLB Trial of Zervimesine
- H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent grant By Investing.com
- Cognition Therapeutics Announces Issuance of Composition of
- H.C. Wainwright reiterates Cognition Therapeutics stock rating ahead of FDA meeting
- H.C. Wainwright reiterates Cognition Therapeutics stock rating ahead of FDA meeting By Investing.com
- Cognition Therapeutics Schedules a Type C Meeting with FDA
Headlines from the last 30 days, linking to the original publishers. See all market news →